2型糖尿病小鼠模型的研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (10): 1196-1200.

• 综述与讲座 • 上一篇

2型糖尿病小鼠模型的研究进展

刘倩¹, 李霞辉², 张学梅¹

¹大连大学医学院,大连 116622, 辽宁;
²大连医科大学,大连 116623, 辽宁

收稿日期:2013-03-21 修回日期:2013-05-20 出版日期:2013-10-26 发布日期:2013-09-30
通讯作者: 张学梅,女,硕士生导师,研究方向:基因工程抗体的制备和糖尿病发病的免疫学机制。E-mail: zhangxue_m@163.com
作者简介:刘倩,女,硕士研究生,研究方向:糖尿病发病免疫学机制的研究。E-mail: liuqianx@126.com

Mouse models of type 2 diabetes mellitus

LIU Qian¹, LI Xia-hui², ZHANG Xue-mei¹

¹Medical College of Dalian University, Dalian 116622, Liaoning, China;
²Dalian Medical University, Dalian 116623, Liaoning, China

Received:2013-03-21 Revised:2013-05-20 Online:2013-10-26 Published:2013-09-30

摘要/Abstract

摘要： 2型糖尿病是一种受遗传因素和环境因素共同影响的疾病,动物模型在糖尿病及其并发症的发病机制、预防和治疗方法的研究中发挥重要作用,当前应用广泛的糖尿病小鼠模型主要有自发性糖尿病小鼠模型、实验性糖尿病小鼠模型和基因工程糖尿病小鼠模型。不同实验方法制备的糖尿病小鼠具有模拟临床糖尿病不同方面的特点,该文对各个模型的发病机制和生理特点等方面进行了阐述,以利于研究者根据各自不同的实验需求和目的选择合适的糖尿病小鼠模型来验证或实现科研设想。

关键词: 2型糖尿病, 小鼠模型

Abstract: Type 2 diabetes was a disease influenced by genetic factors and environmental factors. Animal models of diatetes were essential tools for the understand of the pathogenesis、prevention and treatment of diabetes and its complications. Diabetes mouse models were normally classified into three classes which were spontaneously induced diabetes mouse, experimentally induced diabetes mouse and transgenic diabetes mouse. Each diabetes mouse only imitated clinical diabetes in some aspects and he characteristics of each model about mechanisms and physiology were described in this article. Researchers should choose the suitable diabetes mouse according to their research purpose.

Key words: Type 2 diabetes mellitus, Mouse model

中图分类号:

R589

刘倩, 李霞辉, 张学梅. 2型糖尿病小鼠模型的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(10): 1196-1200.

LIU Qian, LI Xia-hui, ZHANG Xue-mei. Mouse models of type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1196-1200.

参考文献

[1] Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000[J]. Diabetes Care, 2005, 28(9): 2130-2135.
[2] Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents[J]. J Pediatr, 2005, 146(5): 693-700.
[3] Leiter EH. Selecting the “right” mouse model for metabolic syndrome and type 2 diabetes research[J]. Methods Mol Biol, 2009, 560: 1-17.
[4] Islam, MS, Loots du T. Experimental rodent models of type 2 diabetes: a review[J]. Methods Find Exp Clin Pharmacol, 2009, 31(4): 249-261.
[5] Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse[J]. J Hered, 1950, 41(12): 317-318.
[6] Asensio C, Cettour-Rose P, Theander-Carrillo C, et al. Changes in glycemia by leptin administration or high- fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis[J]. Endocrinology, 2004, 145(5): 2206-2213.
[7] 刘海玲,谭渊明,刘昭前. 瘦素抵抗和基因多态性与2型糖尿病的关系[J]. 中国临床药理学与治疗学, 2007,12(3): 262-265.
[8] Coleman DL, Hummel KP. Hyperinsulinemia in preweaning diabetes (db) mice[J]. Diabetolo- gia, 1974, 10 Suppl: 607-610.
[9] Stepanova OI, Karkischenko NN, Baranova OV, et al. Mutant C57Bl/Kslepr(db/+) mice as a genetic model of type 2 diabetes mellitus[J]. Bull Exp Biol Med, 2007, 144(6): 813-816.
[10] Garris DR, Garris BL. Genomic modulation of diabetes (db/db) and obese (ob/ob) mutation-induced hypercytolipidemia: cytochemical basis of female reproductive tract involution[J]. Cell Tissue Res, 2004, 316(2): 233-241.
[11] Nakamura M, Yamada K. Studies on a diabetic (KK) strain of the mouse[J]. Diabetologia, 1967, 3(2): 212-221.
[12] Suto J. Coincidence of loci for glucosuria and obesity in type 2 diabetes-prone KK-A^y mice[J]. Med Sci Monit, 2008, 14(2): CR65-74.
[13] Bielschowsky F, Bielschowsky M. The New Zealand strain of obese mice; their response to stilboestrol and to insulin[J]. Aust J Exp Biol Med Sci, 1956, 34(3): 181-198.
[14] Crofford OB, Davis Jr CK. Growth Characteristics, Glucose Tolerance and Insulin Sensitivity of New Zealand Obese Mice[J]. Metabolism, 1965, 14: 271-280.
[15] Kluge R, Scherneck S, Schurmann A, et al. Pathophysiology and genetics of obesity and diabetes in the New Zealand obese mouse: a model of the human metabolic syndrome[J]. Methods Mol Biol, 2012, 933: 59-73.
[16] Wator L, Razny U, Balwierz A, et al. Impaired leptin activity in New Zealand Obese mice: model of angiogenesis[J]. Genes Nutr, 2008, 3(3/4): 177-180.
[17] Mirhashemi F, Scherneck S, Kluth O, et al. Diet dependence of diabetes in the New Zealand Obese (NZO) mouse: total fat, but not fat quality or sucrose accelerates and aggravates diabetes[J]. Exp Clin Endocrinol Diabetes, 2011, 119(3): 167-171.
[18] Ueda H, Ikegami H, Kawaguchi Y, et al. Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse[J]. Diabetologia, 2000, 43(7): 932-938.
[19] Suzuki W, Iizuka S, Tabuchi M, et al., A new mouse model of spontaneous diabetes derived from ddY strain[J]. Exp Anim, 1999, 48(3): 181-189.
[20] Iizuka S, Suzuki W, Tabuchi M, et al. Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity[J]. Exp Anim, 2005, 54(1): 71-83.
[21] Allan MF, Eisen EJPomp D. The M16 mouse: an outbred animal model of early onset polygenic obesity and diabesity[J]. Obes Res, 2004, 12(9): 1397-1407.
[22] Houssay BA, Martinez C. Experimental Diabetes and Diet[J]. Science, 1947, 105(2734): 548-549.
[23] Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes[J]. Diabetes, 2004, 53 Suppl 3: S215-219.
[24] Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes[J]. Diabetologia, 2008, 51(2): 216-226.
[25] 王彤, 唐秀群, 赵泳谊, 等. 链脲佐菌素和高脂肪饲料诱导的实验性型糖尿病小鼠模型[J]. 中国糖尿病杂志, 2000, 8(2): 111-112.
[26] Masiello P, Broca C, Gross R, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide[J]. Diabetes, 1998, 47(2): 224-229.
[27] Nakamura T, Terajima T, Ogata T, et al. Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide[J]. Biol Pharm Bull, 2006, 29(6): 1167-1174.
[28] Srinivasan K, Ramarao P, Animal models in type 2 diabetes research: an overview[J]. Indian Journal of Medical Resesrch, 2007, 125(3): 451-472.
[29] Dorner AJ, Schaub R. Evaluating the biological complexity of animal models of human disease and emerging therapeutic modalities[J]. Curr Opin Pharmacol, 2010, 10(5): 531-533.
[30] Lederman L. Animal models of human disease[J]. Biotechniques, 2007, 42(3): 265-269.

2型糖尿病小鼠模型的研究进展

Mouse models of type 2 diabetes mellitus

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[5]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[6]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[7]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[8]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[9]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[10]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[11]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.
[12]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.
[13]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[14]	徐永霞, 谢明珠, 宫牧雪, 黄嘉莹, 赵丽, 朱德发. 25羟维生素D对老年2型糖尿病患者胰岛β细胞功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1021-1026.
[15]	赵海玲, 张浩军, 赵婷婷, 严美花, 董晞, 马亮, 李平. PNPLA2基因多态性与中国汉族2型糖尿病患者缺血性脑卒中的相关性研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 664-669.